Just presented at ASCO24: IMROZ results by C. Ola Landgren – ASCO

ASCO shared a post on X:

“Just presented at American Society of Clinical Oncology 2024 (ASCO24), IMROZ results- lsatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) significantly improved Progression-Free Survival (PFS) in patients with transplant-ineligible, newly diagnosed Multiple Myeloma versus Velcade, Revlimid and dexamethasone (VRd) with no new safety concerns.”

Additional information
Source: ASCO/X